BioSpace News Archive

Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced it will present data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) in an oral presentation at the International Conference on Malignant Lymphoma (ICML) on June 13–17, 2023.

Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously that the data from Eisai’s Phase 3 Clarity AD clinical trial confirms the clinical benefit of LEQEMBI® 100 mg/mL injection for intravenous use for the treatment of Alzheimer’s disease.

egnite, Inc. and JenaValve Technology, Inc. are pleased to announce a strategic partnership aimed to shed light on the care paradigm and associated outcomes of patients with aortic regurgitation.

Pursuant to the signing of a Letter of Intent in December 2022, Asep Medical Holdings Inc. is delighted to announce it has signed a definitive agreement for a joint venture with Bahrain-based international investment consultancy firm, Seaspring W.L.L., to advance regulatory approval and commercialization of the Company’s sepsis diagnosis technology in the Kingdom of Bahrain and the Middle East and North Africa.

Mirum Pharmaceuticals, Inc. announced that on June 9, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 43,150 shares of common stock and 22,030 restricted stock units to nine new employees under Mirum’s 2020 Inducement Plan.